FollowMyHealth Patient Portal

James J. Hsieh, MD, PhD

Professor, Oncology

Division of Medical Oncology
Molecular Oncology & Developmental Therapeutics

Specialty Areas

Medical Oncology
Kidney Cancer

Hospital Affiliations

Barnes-Jewish Hospital

Languages

Mandarin
Taiwanese

Areas of Clinical Interest

Kidney cancer, rare kidney cancer, targeted therapy, immunotherapy, precision medicine

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110
Phone: 314-747-7222

Education

Education

Fellowship, Medical Oncology: Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 2003
Fellowship, Medical Oncology: Washington University School of Medicine, St. Louis, MO 2000
Residency, Internal Medicine: Barnes-Jewish Hospital, St. Louis, MO 1999
PhD, Molecular Biology: Johns Hopkins University School of Medicine, Baltimore, MD 1996
Medical Degree: Taipei Medical University, Taipei, Taiwan 1990

Publication & Research

Publication & Research

Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ
J Pathol. 2017 Dec 19; doi: 10.1002/path.5022.

PMID:
    29266437
    [PubMed - as supplied by publisher]
Related citations


ΔNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival.
Wang GX, Tu HC, Dong Y, Skanderup AJ, Wang Y, Takeda S, Ganesan YT, Han S, Liu H, Hsieh JJ, Cheng EH
Cell Rep. 2017 Dec 5; 21(10)2926-2939. doi: 10.1016/j.celrep.2017.11.030.

PMID:
    29212036
    [PubMed - in process]
Related citations


Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.
Manley BJ, Reznik E, Ghanaat M, Kashan M, Becerra MF, Casuscelli J, Tennenbaum D, Redzematovic A, Carlo MI, Sato Y, Arcila M, Voss MH, Feldman DR, Motzer RJ, Russo P, Coleman J, Hsieh JJ, Hakimi AA
Urol Oncol. 2017 Nov 10; pii: S1078-1439(17)30549-5. doi: 10.1016/j.urolonc.2017.10.012.

PMID:
    29132830
    [PubMed - as supplied by publisher]
Related citations


Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, Socci N, Carlo MI, Lee CH, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Cheng EH, Hakimi AA, Hsieh JJ
Eur Urol Focus. 2017 Oct 20; pii: S2405-4569(17)30237-7. doi: 10.1016/j.euf.2017.09.016.

PMID:
    29066084
    [PubMed - as supplied by publisher]
Related citations


Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?
Casuscelli J, Hsieh JJ
Eur Urol. 2018 Jan; 73(1)69-70. doi: 10.1016/j.eururo.2017.09.026.

PMID:
    29032154
    [PubMed - in process]
Related citations


<i>SETD2</i> alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL
Blood. 2017 Dec 14; 130(24)2631-2641. doi: 10.1182/blood-2017-03-775569.

PMID:
    29018079
    [PubMed - indexed for MEDLINE]
Related citations


Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA
Eur Urol Focus. 2017 Sep 23; pii: S2405-4569(17)30212-2. doi: 10.1016/j.euf.2017.09.008.

PMID:
    28951115
    [PubMed - as supplied by publisher]
Related citations


SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer.
Nargund AM, Osmanbeyoglu HU, Cheng EH, Hsieh JJ
Mol Cell Oncol. 2017; 4(4)e1342747. doi: 10.1080/23723556.2017.1342747.

PMID:
    28868352
    [PubMed]
Related citations


Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ
Nat Commun. 2017 Aug 4; 8(1)199. doi: 10.1038/s41467-017-00289-x.

PMID:
    28775315
    [PubMed - in process]
Related citations


Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee CH, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ
Eur Urol Focus. 2016 Aug 25; pii: S2405-4569(16)30113-4. doi: 10.1016/j.euf.2016.08.005.

PMID:
    28753786
    [PubMed - as supplied by publisher]
Related citations


Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA
Eur Urol Focus. 2016 Jul 16; pii: S2405-4569(16)30094-3. doi: 10.1016/j.euf.2016.06.015.

PMID:
    28753773
    [PubMed - as supplied by publisher]
Related citations


Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients.
Rosenzweig B, Rubinstein ND, Reznik E, Shingarev R, Juluru K, Akin O, Hsieh JJ, Jaimes EA, Russo P, Susztak K, Coleman JA, Hakimi AA
PLoS One. 2017; 12(7)e0180350. doi: 10.1371/journal.pone.0180350.

PMID:
    28727768
    [PubMed - indexed for MEDLINE]
Related citations


Recommendations for the Management of Rare Kidney Cancers.
Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A
Eur Urol. 2017 Dec; 72(6)974-983. doi: 10.1016/j.eururo.2017.06.040.

PMID:
    28720391
    [PubMed - in process]
Related citations


Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH
Nat Commun. 2017 Jul 17; 816078. doi: 10.1038/ncomms16078.

PMID:
    28714472
    [PubMed - in process]
Related citations


Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.
Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ
JCI Insight. 2017 Jun 15; 2(12)pii: 92688. doi: 10.1172/jci.insight.92688.

PMID:
    28614790
    [PubMed - as supplied by publisher]
Related citations


Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, Coskey D, Nanjangud GJ, Voss MH, Feldman DR, Hsieh JJ, Hakimi AA, Chen YB, Motzer RJ, Lee CH
Clin Genitourin Cancer. 2017 Dec; 15(6)e987-e994. doi: 10.1016/j.clgc.2017.04.012.

PMID:
    28558987
    [PubMed - in process]
Related citations


Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA
Nat Commun. 2017 May 10; 815165. doi: 10.1038/ncomms15165.

PMID:
    28489074
    [PubMed - in process]
Related citations


Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA
Urol Oncol. 2017 Aug; 35(8)532.e7-532.e13. doi: 10.1016/j.urolonc.2017.03.015.

PMID:
    28408295
    [PubMed - in process]
Related citations


The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, Lekaye CL, Koutcher JA, Leslie CS, Creighton CJ, Weinhold N, Lee W, Tickoo SK, Wang Z, Cheng EH, Hsieh JJ
Cell Rep. 2017 Mar 21; 18(12)2893-2906. doi: 10.1016/j.celrep.2017.02.074.

PMID:
    28329682
    [PubMed - indexed for MEDLINE]
Related citations


Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V
Nat Rev Dis Primers. 2017 Mar 9; 317009. doi: 10.1038/nrdp.2017.9.

PMID:
    28276433
    [PubMed - in process]
Related citations

Areas of Research Interest

In 2011, Dr. Hsieh founded the Translational Kidney Cancer Research Program (TKCRP) to enable seamless collaboration among basic, preclinical and clinical scientists. The team employs state-of-art platforms and clinical trial materials to integrate kidney cancer genomics, transcriptomics, proteomics, metabolomics, and therapeutics. His group pioneered a novel metabolic analytic algorithm (Metabologram) to interrogate human cancer metabolism in 2016. His laboratory recently established novel kidney cancer mouse models that recapitulate prevalent human kidney cancer mutations. Through studying kidney cancer, Dr. Hsieh proposed a novel cancer evolution (braided cancer river) model in 2015, capitalizing phenotypically, mechanistically convergent events to guide effective cancer therapy and overcome treatment-resistance. His primary translational goals are to develop novel mechanism-based, personalized therapeutics to prevent recurrence in high-risk patients and provide cure to significant number of metastatic kidney cancer patients.